Wedbush lowered the firm’s price target on Ideaya Biosciences to $52 from $54 after adjusting assumption of approval timing, while keeping an Outperform rating on the shares. The firm notes Ideaya held an investor webcast to share positive data update for daro in uveal melanoma in the neoadjuvant setting, and provided an update from a recent FDA Type C meeting for a registrational study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences should be bought on weakness, says Citi
- Ideaya Biosciences price target raised to $48 from $47 at Goldman Sachs
- Ideaya Biosciences price target lowered to $66 from $68 at Stifel
- Ideaya Type C meeting outcome ‘best case,’ says Oppenheimer
- Ideaya Biosciences announces interim darovasertib trial data